29 September 2016 - CADTH has published its final outcome for Lynparza.

CADTH has not recommended the use of olaparib for use as monotherapy maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response to platinum-based chemotherapy. The Expert Review Committee was not convinced that olaparib has a net clnical benefit over placebo due to limitations in the evidence from the non-comparative phase II clinical trial.

Read CADTH's final recommendation for Lynparza